Phase II Trial of PS-341 (Bortezomib) in Patients With Previously Treated Advanced Urothelial Tract Transitional Cell Carcinoma
Phase of Trial: Phase II
Latest Information Update: 04 Jun 2013
At a glance
- Drugs Bortezomib (Primary)
- Indications Bladder cancer; Pelvic cancer; Renal cancer; Urogenital cancer
- Focus Therapeutic Use
- 06 Oct 2009 Actual end date (Aug 2009) added as reported by ClinicalTrials.gov.
- 06 Oct 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 19 Sep 2005 New trial record.